CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced that initial patients have been enrolled in the ADAPT 2.0 Clinical Study, a prospective, multi-center, open-label, observational study evaluating the effectiveness, safety and clinical outcomes of the ADAPT 2.0 technique using the Zoom Stroke System to treat patients with acute ischemic stroke. “This study is designe
Imperative Care Initiates ADAPT 2.0 Study Evaluating Advanced Clinical Technique Designed to Simplify Acute Ischemic Stroke Treatment
